Your browser doesn't support javascript.
loading
Chronic hepatitis C: Diagnosis and treatment made easy.
Abu-Freha, Naim; Mathew Jacob, Binil; Elhoashla, Ali; Afawi, Zaid; Abu-Hammad, Talab; Elsana, Foad; Paz, Sergey; Etzion, Ohad.
Afiliação
  • Abu-Freha N; The Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Mathew Jacob B; Medical School for International Health, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Elhoashla A; Clalit Health Services, Beer-Sheva, Israel.
  • Afawi Z; Clalit Health Services, Beer-Sheva, Israel.
  • Abu-Hammad T; Erasmus MC, Rotterdam, The Netherlands.
  • Elsana F; Clalit Health Services, Beer-Sheva, Israel.
  • Paz S; Clalit Health Services, Beer-Sheva, Israel.
  • Etzion O; Clalit Health Services, Beer-Sheva, Israel.
Eur J Gen Pract ; 28(1): 102-108, 2022 Dec.
Article em En | MEDLINE | ID: mdl-35579223
BACKGROUND: Hepatitis C Virus (HCV) is a common cause of chronic liver disease and its ensuing complications. In the last years, there has been a revolution of the treatment for patients with HCV regarding efficacy, simplicity, safety and duration of treatment. The role of the family physician is vital in all steps of care: screening, diagnosis, linkage to treatment, treatment and follow-up. OBJECTIVES: This review aims to summarise the family physician and the important updated recommendations for diagnosis and treatment of patients with chronic HCV. METHODS: The updated recommendations were reviewed and summarised in a short and simple review. RESULTS: Patients with any risk factor for HCV should first be screened for HCV antibodies. In the case of positive antibodies, reflex testing for RNA polymerase chain reaction (PCR) should be done without waiting for genotype. For patients with positive PCR, fibrosis assessment should be conducted using laboratory panels (Fibrosis-4 index (FIB-4) or aspartate aminotransferase to platelet ratio index (APRI)); if advanced fibrosis is suspected, additional non-invasive fibrosis assessment is needed, such as fibrotest or liver elastography. Naïve non-cirrhotic or compensated cirrhosis (Child-Pugh-Score A) could be treated with pangenotypic drugs, Glecaprevir/pibrentasvir (Maviret) for eight weeks, or Sofosbuvir/velpatasvir (Epclusa) for 12 weeks. CONCLUSION: Patients without advanced fibrosis and comorbidities can be treated by the educated family physician. However, patients with comorbidities, cirrhosis or coinfection (HIV, Hepatitis B Virus (HBV)) should be referred to the liver clinic. In case of screening patients with risk factors or likelihood of dormant HCV, health organisations should provide the appropriate resources, logistics, finances and workforce.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatite C Crônica Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatite C Crônica Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article